实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
PRACTICAL JOURNAL OF CARDIAC CEREBRAL PNEUMAL AND VASCULAR DISEASE
2014年
7期
33-34
,共2页
呼吸窘迫综合征,成人%甲泼尼龙%炎性因子%治疗结果
呼吸窘迫綜閤徵,成人%甲潑尼龍%炎性因子%治療結果
호흡군박종합정,성인%갑발니룡%염성인자%치료결과
Respiratory distress syndrome,adult%Methylprednisolone%Inflammatory factors%Treatment outcome
目的：探讨不同剂量甲泼尼龙对急性呼吸窘迫综合征（ARDS）患者炎性因子及治疗效果的影响。方法选取2010-2013年我院收治的 ARDS 患者60例，将其随机分为 A、B、C 3组，各20例。3组患者均给予常规治疗，在常规治疗基础上 B组患者给予甲泼尼龙80 mg/ d 静脉注射、C组患者给予甲泼尼龙500 mg/ d 静脉注射，疗程为3d。观察3组患者治疗前、治疗后3d和7d血浆C反应蛋白（CRP）、纤维蛋白原（FIB）及降钙素原（PCT）水平变化，记录3组患者治疗前后氧合指数、急性生理和慢性健康评分系统Ⅱ评分（APACHEⅡ评分）、住院天数和病死率。结果治疗前3组患者 CRP、FIB 及 PCT 水平比较，差异无统计学意义（P >0.05）。治疗后3d和7dB组和C组患者 CRP、FIB 及 PCT 水平低于A组，C组上述指标低于B组（P <0.05）。治疗前3组患者氧合指数、APACHEⅡ评分比较，差异均无统计学意义（P >0.05）。治疗后B组和C组氧合指数高于A组，C组高于B组（ P <0.05）；A-PACHEⅡ评分低于A组，C组低于B组（P <0.05）；病死率和住院天数低于A组（P <0.05）。结论甲泼尼龙治疗ARDS 可以明显抑制患者炎性因子水平，有助于提高治疗效果，且较大剂量甲泼尼龙疗效更显著。
目的：探討不同劑量甲潑尼龍對急性呼吸窘迫綜閤徵（ARDS）患者炎性因子及治療效果的影響。方法選取2010-2013年我院收治的 ARDS 患者60例，將其隨機分為 A、B、C 3組，各20例。3組患者均給予常規治療，在常規治療基礎上 B組患者給予甲潑尼龍80 mg/ d 靜脈註射、C組患者給予甲潑尼龍500 mg/ d 靜脈註射，療程為3d。觀察3組患者治療前、治療後3d和7d血漿C反應蛋白（CRP）、纖維蛋白原（FIB）及降鈣素原（PCT）水平變化，記錄3組患者治療前後氧閤指數、急性生理和慢性健康評分繫統Ⅱ評分（APACHEⅡ評分）、住院天數和病死率。結果治療前3組患者 CRP、FIB 及 PCT 水平比較，差異無統計學意義（P >0.05）。治療後3d和7dB組和C組患者 CRP、FIB 及 PCT 水平低于A組，C組上述指標低于B組（P <0.05）。治療前3組患者氧閤指數、APACHEⅡ評分比較，差異均無統計學意義（P >0.05）。治療後B組和C組氧閤指數高于A組，C組高于B組（ P <0.05）；A-PACHEⅡ評分低于A組，C組低于B組（P <0.05）；病死率和住院天數低于A組（P <0.05）。結論甲潑尼龍治療ARDS 可以明顯抑製患者炎性因子水平，有助于提高治療效果，且較大劑量甲潑尼龍療效更顯著。
목적：탐토불동제량갑발니룡대급성호흡군박종합정（ARDS）환자염성인자급치료효과적영향。방법선취2010-2013년아원수치적 ARDS 환자60례，장기수궤분위 A、B、C 3조，각20례。3조환자균급여상규치료，재상규치료기출상 B조환자급여갑발니룡80 mg/ d 정맥주사、C조환자급여갑발니룡500 mg/ d 정맥주사，료정위3d。관찰3조환자치료전、치료후3d화7d혈장C반응단백（CRP）、섬유단백원（FIB）급강개소원（PCT）수평변화，기록3조환자치료전후양합지수、급성생리화만성건강평분계통Ⅱ평분（APACHEⅡ평분）、주원천수화병사솔。결과치료전3조환자 CRP、FIB 급 PCT 수평비교，차이무통계학의의（P >0.05）。치료후3d화7dB조화C조환자 CRP、FIB 급 PCT 수평저우A조，C조상술지표저우B조（P <0.05）。치료전3조환자양합지수、APACHEⅡ평분비교，차이균무통계학의의（P >0.05）。치료후B조화C조양합지수고우A조，C조고우B조（ P <0.05）；A-PACHEⅡ평분저우A조，C조저우B조（P <0.05）；병사솔화주원천수저우A조（P <0.05）。결론갑발니룡치료ARDS 가이명현억제환자염성인자수평，유조우제고치료효과，차교대제량갑발니룡료효경현저。
Objective To discuss the effect of different doses of Methylprednisolone on inflammatory factors and effica-cy in patients with acute respiratory distress syndrome(ARDS). Methods 60 ARDS patients in our hospital from 2012 to 2013 were chosen,and they were randomly divided groups A,B,C,each of 20 cases. All patients were given conventional therapy, group B was given intravenous injection of Methylprednisolone,80 mg/ d,group C was given intravenous injection of Methylpred-nisolone,500 mg/ d. All patients treated for 3 days. The levels of C - reactive protein(CRP),fibrinogen(FIB)and procalci-tonin(PCT)were detected before treatment,3 days and 7 days after treatment,and oxygenation index,APACHEⅡ score, hospitalization days and mortality were observed. Results Before treatment,there was no significant differences in the levels of CRP,FIB and PCT among the three groups(P > 0. 05). 3 days and 7 days after treatment,the levels of CRP,FIB and PCT in groups B and C were lower than those of group A,group C were lower than those of group B(P < 0. 05). Before treatment, there was no significant differences in oxygenation index,APACHEⅡ score among the three groups(P > 0. 05). After treat-ment,the oxygenation index in groups B and C was higher than that of group A,group C were higher than that of group B(P <0. 05);APACHEⅡ score were lower than that of group A,group C was lower than that of group B(P < 0. 05);hospitalization days and mortality were lower than those of group A(P < 0. 05). Conclusion Methylprednisolone can significantly inhibit the inflammatory factor,help to improve the therapeutic effect in patients with ARDS,and the effect of large dose of Methylpred-nisolone is better.
